Cargando…

Biological therapy for ulcerative colitis

Ulcerative colitis (UC) is a major form of inflammatory bowel disease (IBD) worldwide. Better understanding of the pathogenesis of UC has led to the development of novel therapeutic agents that target specific mediators of the inflammatory cascade. A number of biological agents have been approved by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arora, Zubin, Shen, Bo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423460/ https://www.ncbi.nlm.nih.gov/pubmed/25344680 http://dx.doi.org/10.1093/gastro/gou070

Ejemplares similares

Risk factors and clinical implication of superimposed Campylobacter jejuni infection in patients with underlying ulcerative colitis
por: Arora, Zubin, et al.
Publicado: (2016)

Current and Emerging Biologics for Ulcerative Colitis
por: Park, Sung Chul, et al.
Publicado: (2015)

Colorectal Dysplasia and Cancer Surveillance in Ulcerative Colitis
por: Reznicek, Emily, et al.
Publicado: (2021)

Medical Therapy of Active Ulcerative Colitis
por: Bürger, Martin, et al.
Publicado: (2015)

Dual Biological Therapy for Ulcerative Colitis with Intractable Pyoderma Gangrenosum
por: Lee, Hae Chan, et al.
Publicado: (2023)

The Microbiome as a Therapy in Pouchitis and Ulcerative Colitis
por: LeBlanc, Jean-Frédéric, et al.
Publicado: (2021)

ULCERATIVE COLITIS
Publicado: (1969)

A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis
por: Stawowczyk, Ewa, et al.
Publicado: (2017)

Selective biologics for ulcerative colitis and Crohn’s disease – clinical utility of vedolizumab
por: Petkau, Jill MV, et al.
Publicado: (2016)

Infliximab in ulcerative colitis
por: Levin, Avi, et al.
Publicado: (2008)

Management of ulcerative colitis
por: Fell, John M, et al.
Publicado: (2016)

Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
por: Na, Soo-Young, et al.
Publicado: (2023)

Biologics for the treatment of pyoderma gangrenosum in ulcerative colitis
por: Arivarasan, K, et al.
Publicado: (2016)

Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn’s disease and ulcerative colitis
por: Hashash, Jana G., et al.
Publicado: (2021)

Biologics in the management of ulcerative colitis – comparative safety and efficacy of TNF-α antagonists
por: Fausel, Rebecca, et al.
Publicado: (2015)

Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia
por: Ooi, Choon Jin, et al.
Publicado: (2019)

Budesonide Foam for Ulcerative Colitis Patients Experiencing Inadequate Response to Biological Therapy
por: Shibuya, Tomoyoshi, et al.
Publicado: (2019)

Potential molecular biomarkers used to predict the response to biological therapies in ulcerative colitis
por: Zhang, Run-Feng, et al.
Publicado: (2021)

Microbiota-Immune Interactions in Ulcerative Colitis and Colitis Associated Cancer and Emerging Microbiota-Based Therapies
por: Popov, Jelena, et al.
Publicado: (2021)

Acute Severe Ulcerative Colitis: Optimal Strategies for Drug Therapy
por: Nakase, Hiroshi
Publicado: (2023)

Tacrolimus for the Treatment of Ulcerative Colitis
por: Matsuoka, Katsuyoshi, et al.
Publicado: (2015)

Golimumab in unresponsive ulcerative colitis
por: Lippert, Elisabeth, et al.
Publicado: (2014)

Radiographical evaluation of ulcerative colitis
por: Deepak, Parakkal, et al.
Publicado: (2014)

Colonoscopic evaluation in ulcerative colitis
por: Paine, Elizabeth R.
Publicado: (2014)

Histological evaluation in ulcerative colitis
por: DeRoche, Tom C., et al.
Publicado: (2014)

Golimumab for the treatment of ulcerative colitis
por: Löwenberg, Mark, et al.
Publicado: (2014)

Golimumab in the treatment of ulcerative colitis
por: Cunningham, Georgina, et al.
Publicado: (2019)

Adherence in ulcerative colitis: an overview
por: Testa, Anna, et al.
Publicado: (2017)

Nutrition and Supplementation in Ulcerative Colitis
por: Radziszewska, Marcelina, et al.
Publicado: (2022)

Infliximab: the evidence for its place in therapy in ulcerative colitis
por: Van Assche, Gert, et al.
Publicado: (2007)

Fecal Microbiota Transplantation for Ulcerative Colitis: An Evolving Therapy
por: Sood, Ajit, et al.
Publicado: (2020)

Second Korean guidelines for the management of ulcerative colitis
por: Choi, Chang Hwan, et al.
Publicado: (2017)

Exploring the Relationship between Biologics and Postoperative Surgical Morbidity in Ulcerative Colitis: A Review
por: Quaresma, Abel Botelho, et al.
Publicado: (2021)

Recent advances and emerging therapies in the non-surgical management of ulcerative colitis
por: Wehkamp, Jan, et al.
Publicado: (2018)

Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis
por: Dart, Robin J, et al.
Publicado: (2017)

Emerging Therapies for Ulcerative Colitis: Updates from Recent Clinical Trials
por: AlAmeel, Turki, et al.
Publicado: (2023)

Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn's Disease in the United States
por: Siegel, Corey A., et al.
Publicado: (2020)

Efficacy of cytapheresis in patients with ulcerative colitis showing insufficient or lost response to biologic therapy
por: Iizuka, Masahiro, et al.
Publicado: (2022)

Identification of key genes and biological processes contributing to colitis associated dysplasia in ulcerative colitis
por: Zhang, Di, et al.
Publicado: (2021)

The role of mesalamine in the treatment of ulcerative colitis
por: Karagozian, Raffi, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_g8lhi01hnktp64cod079k250sp